IKBKB and cancer: Subjecting quinoxaline analog libraries to both unbiased and biased screening strategies identified an orally bioavailable, non-ATP competitive inhibitor of nuclear factor kappa-B kinase subunit beta (IKKβ) inhibitor that exhibited anti-cancer effects in mouse models [18,19,20,21,22,23,24].